科研之友
微信
新浪微博
Facebook
分享链接
摘要
<正>The race is on again in DNA sequencing. In what has been described as “the year of the big shake-up”[1], a wave of new competitors entered the market in 2022, challenging industry leader Illumina (San Diego, CA, USA). New systems from both Illumina and emerging rivals are now poised to push costs down-closing in on the oft-cited goal of 100 USD per genome.
